[Congressional Record Volume 171, Number 34 (Thursday, February 20, 2025)]
[Senate]
[Page S1215]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 597. Mr. MERKLEY submitted an amendment intended to be proposed by 
him to the concurrent resolution S. Con. Res. 7, setting forth the 
congressional budget for the United States Government for fiscal year 
2025 and setting forth the appropriate budgetary levels for fiscal 
years 2026 through 2034; which was ordered to lie on the table; as 
follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO REDUCING 
                   FEDERAL HEALTH PROGRAM SPENDING FOR 
                   PRESCRIPTION DRUGS.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     reducing health care costs, which may include legislation 
     establishing international reference prices so the United 
     States may purchase prescription drugs at the lowest prices 
     available among similarly developed countries, requiring 
     pharmaceutical manufacturers to report annually the amount of 
     taxpayer dollars used to benefit manufacturers' research and 
     development efforts, or other mechanisms to purchase 
     prescription drugs at lower prices, by the amounts provided 
     in such legislation for those purposes, provided that such 
     legislation would not increase the deficit over the period of 
     the total of fiscal years 2025 through 2034.
                                 ______